23,217 Shares in Voyager Therapeutics, Inc. (NASDAQ:VYGR) Bought by Cornercap Investment Counsel Inc.

Cornercap Investment Counsel Inc. purchased a new stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the fourth quarter, Holdings Channel reports. The firm purchased 23,217 shares of the company’s stock, valued at approximately $196,000.

Several other hedge funds have also recently added to or reduced their stakes in VYGR. Gladius Capital Management LP bought a new stake in Voyager Therapeutics in the 3rd quarter worth approximately $25,000. Ameritas Investment Partners Inc. bought a new position in shares of Voyager Therapeutics during the 2nd quarter valued at $30,000. UBS Group AG purchased a new position in Voyager Therapeutics in the 1st quarter worth $39,000. China Universal Asset Management Co. Ltd. bought a new stake in Voyager Therapeutics in the fourth quarter worth $43,000. Finally, PDT Partners LLC purchased a new stake in Voyager Therapeutics during the second quarter valued at about $60,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $7.74 on Thursday. Voyager Therapeutics, Inc. has a 1 year low of $6.06 and a 1 year high of $14.34. The stock has a market capitalization of $420.28 million, a P/E ratio of 2.50 and a beta of 0.96. The company’s 50-day moving average is $8.79 and its 200 day moving average is $7.95.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The firm had revenue of $90.06 million during the quarter, compared to analyst estimates of $4.95 million. Research analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Wells Fargo & Company raised Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $9.00 to $14.00 in a research note on Tuesday, January 2nd. Citigroup initiated coverage on shares of Voyager Therapeutics in a research note on Thursday, March 7th. They issued a “buy” rating and a $16.00 target price on the stock. HC Wainwright started coverage on shares of Voyager Therapeutics in a report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price target on the stock. StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 9th. Finally, Guggenheim began coverage on Voyager Therapeutics in a research note on Tuesday, March 26th. They issued a “buy” rating and a $22.00 target price on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.